Gamida Cell Ltd.
Sector: Biotechnology - Therapeutics
Medical Field: Oncology
Technological Field: Bone Marrow Transplantation, Stem Cell Therapy
Year Established: 1998
Gamida-Cell is a leader in the expansion of stem cell therapeutics utilizing small molecules to stimulate stem cell self-renewal, with limited differentiation. Gamida Cell's technologies are simple, reversible, do not involve genetic interference, and are easily scalable.
The lead product NiCord is currently in phase 2 clinical study in patients with hematological malignancies. A randomized controlled phase 3 is planned to begin in 2016 in the US and Europe. Additional two phase I/II studies are ongoing in the US and Europe, in patients with sickle cell disease and thalassemia.
In addition, Gamida Cell is developing a NK cell product for immune therapy of cancer. Two phase I/II studies with this product are planned to begin in 2015/2016 in the US. . Gamida-Cell enjoys scientific collaboration with leading investigators, clinicians, and research groups around the world.